Programmatically selected multidrug-resistant strains drive the emergence of extensively drug-resistant tuberculosis in South Africa by Muller, Borna et al.
Programmatically Selected Multidrug-Resistant Strains
Drive the Emergence of Extensively Drug-Resistant
Tuberculosis in South Africa
Borna Mu¨ller1,2,3., Violet N. Chihota1,4., Manormoney Pillay5, Marisa Klopper1, Elizabeth M. Streicher1,
Gerrit Coetzee6, Andre Trollip1, Cindy Hayes7, Marlein E. Bosman8, Nicolaas C. Gey van Pittius1,
Thomas C. Victor1, Sebastien Gagneux2,3, Paul D. van Helden1, Robin M. Warren1*
1DST/NRF Centre of Excellence for Biomedical Tuberculosis Research/MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics,
Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa, 2 Swiss Tropical and Public Health Institute, Basel, Switzerland, 3University of
Basel, Basel, Switzerland, 4 The Aurum Institute for Health Research, Johannesburg, South Africa, 5Medical Microbiology and Infection Control, University of KwaZulu-
Natal, Durban, South Africa, 6National TB Reference Laboratory, National Institute for Communicable Diseases, National Health laboratory Services, Johannesburg, South
Africa, 7National Health Laboratory Service, Port Elizabeth, South Africa, 8National Health Laboratory Service, Green Point, Cape Town, South Africa
Abstract
Background: South Africa shows one of the highest global burdens of multidrug-resistant (MDR) and extensively drug-
resistant (XDR) tuberculosis (TB). Since 2002, MDR-TB in South Africa has been treated by a standardized combination
therapy, which until 2010 included ofloxacin, kanamycin, ethionamide, ethambutol and pyrazinamide. Since 2010,
ethambutol has been replaced by cycloserine or terizidone. The effect of standardized treatment on the acquisition of XDR-
TB is not currently known.
Methods: We genetically characterized a random sample of 4,667 patient isolates of drug-sensitive, MDR and XDR-TB cases
collected from three South African provinces, namely, the Western Cape, Eastern Cape and KwaZulu-Natal. Drug resistance
patterns of a subset of isolates were analyzed for the presence of commonly observed resistance mutations.
Results: Our analyses revealed a strong association between distinct strain genotypes and the emergence of XDR-TB in
three neighbouring provinces of South Africa. Strains predominant in XDR-TB increased in proportion by more than 20-fold
from drug-sensitive to XDR-TB and accounted for up to 95% of the XDR-TB cases. A high degree of clustering for drug
resistance mutation patterns was detected. For example, the largest cluster of XDR-TB associated strains in the Eastern Cape,
affecting more than 40% of all MDR patients in this province, harboured identical mutations concurrently conferring
resistance to isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin, ethionamide, kanamycin, amikacin and
capreomycin.
Conclusions: XDR-TB associated genotypes in South Africa probably were programmatically selected as a result of the
standard treatment regimen being ineffective in preventing their transmission. Our findings call for an immediate
adaptation of standard treatment regimens for M/XDR-TB in South Africa.
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Introduction
The emergence of multidrug-resistant (MDR) and extensively
drug-resistant (XDR) tuberculosis (TB) threatens disease control
efforts throughout the world [1–3]. Drug-resistant TB may be
acquired if bacteria harbouring spontaneously emerging drug
resistance mutations (Table 1) are positively selected due to e.g.
inadequate treatment regimens, poor drug quality or patient non-
compliance [2,4–6]. Alternatively, drug-resistant TB may also
occur through the transmission of already resistant strains; termed
primary resistance. High rates of primary resistance reflect, poor
transmission control essentially due to delays in drug susceptibility
testing and initiation of appropriate treatment [2,5].
Globally, in 2011, there were an estimated 310,000 incident
cases of MDR-TB among cases reported to have tuberculosis of
which 9% were XDR-TB [3,4]. Increasing incidence rates for
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MDR-TB were recorded in several settings with South Africa
being among the most severely affected countries [1,7,8]. In South
Africa, 10% of all TB cases are believed to be MDR-TB of which
again one-tenth are XDR-TB [1,7,8]. Highest rates of MDR and
XDR-TB were notified for the Western Cape, Eastern Cape and
KwaZulu-Natal provinces [9] with treatment success rates below
50% for MDR-TB and considerably poorer outcomes for XDR-
TB [10,11]. There is convincing evidence that MDR-TB in South
Africa is caused mostly by the transmission of MDR strains, as
suggested by well-documented clonal outbreaks and elevated rates
of primary resistance (in some places as high as 80%) among
MDR-TB cases [12–17]. Similarly, transmission of MDR strains is
likely to be a main driver of MDR-TB in many other high-burden
countries [2,5,18].
New TB patients in South Africa are treated according to WHO
guidelines with isoniazid (H), rifampicin (R), ethambutol (E) and
pyrazinamide (Z) [19]. Since 2002, MDR-TB treatment is also
standardized and until 2010 included a fluoroquinolone (FQ;
mostly ofloxacine [Ofx]), kanamycin (Km), ethionamide (Eto), E
and Z [20]. This regimen neglected high proportions of E and Z
resistance among MDR-TB cases and cross-resistance to Eto if
infecting strains previously acquired an inhA promoter mutation
(Table 1) [21,22]. An only marginally improved MDR-TB
regimen was implemented in 2010, which replaced E with
cycloserine or terizidone (Cs/Trd) [20]. Standardized chemother-
apy for MDR-TB is necessary in resource-limited settings where
drug susceptibility testing (DST) cannot be performed regularly
[19]. The design of standardized regimens however, requires the
prior determination of the spectrum of resistances present in the
community [19]. Culture-based resistance surveys not incorporat-
ing strain genotyping data do not enable examining whether
detected resistances are transmitted jointly (by the same strain) or
independently (by different strains). The absence of this knowledge
has important implications for the design of standardized
treatment regimens.
Previous studies in South Africa observed an association of
specific genotypes of M. tuberculosis with XDR-TB [23]. Specifi-
cally, the R220 genotype, a subgroup of the typical Beijing family
of strains, the R86 genotype, a subgroup of ‘‘atypical’’ Beijing
strains and the F15/LAM4/KZN genotype, a subgroup of the
LAM4 family, were identified as commonly transmitted drug-
resistant strains in the Western Cape, Eastern Cape and KwaZulu-
Natal, respectively [15,16,23–26]. In order to elucidate whether
and how standardized treatment impacted the strain population
structure of drug-sensitive and drug-resistant M. tuberculosis in
South Africa, we characterized in detail an extensive collection of
clinical TB isolates from these provinces and analyzed resistance
patterns of XDR-TB associated strains.
Materials and Methods
Ethics statement
This study was approved by the Ethics Committees of
Stellenbosch University and the University of KwaZulu-Natal.
The Stellenbosch Health Research Ethics Committee approved a
waiver of consent for the retrospective genotypic analysis of
routinely collected M. tuberculosis isolates after patient identifiers
were removed. The University of KwaZulu-Natal Ethic Commit-
tee approved the prospective collection and genotyping of M.
tuberculosis isolates after obtaining written consent.
Study population, routine culture and drug susceptibility
testing
A comprehensive sample of clinical drug-resistant TB isolates
collected during different time periods from the whole area of the
Western Cape, Eastern Cape and KwaZulu-Natal province were
analysed (Figure 1). Only one isolate per patient was included in
the study. Subsets of this sample collection were used previously to
describe the population structure of MDR M. tuberculosis strains in
these provinces [23] and drug resistance mutations of strains of the
Eastern Cape Province [27]. These isolates characterised formerly
were further complemented with a comparable, random sample of
diagnosed drug-sensitive and mono-/poly-resistant isolates in
order to analyse a larger spectrum of resistance patterns and a
Table 1. Drug resistance-associated genetic regions analyzed.
Genetic region Region covered* No. of base-pairs Resistance
katG gene 2154968…2155387 420 H
inhA promoter 1673261…1673506 246 H, Eto
rpoB gene 760822…761258 437 R
embB gene 4247302…4247561 260 E
pncA gene 2288652…2289266 615 Z
rrs gene (around nucleotide position 513) 1472283…1472852 570 S
rrs gene (around nucleotide position 1401) 1473184…1473373 190 Km, Am, Cm
gyrA gene 7355…7698 344 Many FQs, e.g. Ofx
*Genetic region covered by PCR with respect to nucleotide positions in H37Rv.
H: Isoniazid.
Eto: Ethionamide.
R: Rifampicin.
E: Ethambutol.
Z: Pyrazinamid.
S: Streptomycin.
Km: Kanamycin.
Am: Amikacin.
Cm: Capreomycin.
FQ: Fluoroquinolone.
Ofx: Ofloxacin.
doi:10.1371/journal.pone.0070919.t001
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wider geographical area compared to previous studies. Routine
culture and DST was performed at the National Health
Laboratory Service (NHLS) in the respective provinces as
described previously [23]. The location of healthcare facilities
attended by the TB patients was recorded to analyze the
geographical distribution of M. tuberculosis genotypes identified.
Definition of drug resistance groups
M. tuberculosis isolates were classified into different drug
resistance groups based on routine DST [23]. Drug-sensitive
isolates were susceptible to all drugs tested (at least H and R).
Mono-/Poly-resistant isolates were resistant to one or multiple
first-line anti-TB drugs but were not MDR. MDR and XDR
isolates were classified according to WHO definitions [19]. Pre-
XDR-TB isolates were defined as MDR-TB isolates with
additional resistance to either a FQ or a second-line injectable
drug (Km, amikacin [Am] or capreomycin [Cm]) but not both.
The MDR sensu stricto (s.s.) group excluded identified pre-XDR
and XDR isolates from MDR isolates.
Genotypic characterization
Initial genotyping of random samples of M. tuberculosis isolates
was done by spoligotyping according to the protocol described by
Kamerbeek et al [28] and the isolates were grouped into
recognized strain families by comparison to previously reported
spoligotype patterns [29,30]. A randomly selected subset of Beijing
isolates from all drug resistance groups from the Western and
Eastern Cape and a subset of only drug-sensitive Beijing isolates
from KwaZulu-Natal were further differentiated into typical
and ‘‘atypical’’ Beijing isolates by PCR (Figure 1) [14].
Computer-based random sampling was applied to randomly
select isolates. Based on similar IS6110 RFLP patterns and
whole genome sequencing data it was previously established that
‘‘atypical’’ Beijing strains in the Western and Eastern Cape
represent one single genotype herein referred to as R86
[14,25,31]. Typical Beijing isolates from the Western Cape
were distinguished into R220 and non-R220 isolates by PCR
(Figure 1) [32]. LAM4 isolates from KwaZulu-Natal were
differentiated into F15/LAM4/KZN and other LAM4 isolates
by IS6110 RFLP analysis (Figure 1) [16]. A random subsample
of identified MDR R86 isolates from the Eastern Cape was
tested for the presence of drug resistance mutations in the inhA
promoter and the genes katG, rpoB, pncA, embB, rrs and gyrA by
PCR amplification of genetic regions commonly observed to
harbour resistance mutations and subsequent sequencing of
these PCR products (Table 1, Figure 1) [33–37]. Similarly, data
from an extensive collection of drug-resistant isolates from the
Western Cape was reviewed for records on Beijing isolates
tested for the presence of resistance mutations in the same
genetic regions (Table 1, Figure 1). However, no data on
streptomycin resistance mutations in rrs were available (Table 1).
Isolates with identical drug resistance mutation patterns were
grouped by pncA mutations, which are highly diverse and may
allow identifying genetically related groups of strains [27].
Figure 1. Selection of study population. Grey boxes indicate sample sets used to analyze the strain population structures in the three South
African provinces. Boxes with striped pattern indicate sample sets used to characterize drug resistance mutation patterns among XDR-TB associated
genotypes. a) Computer-based random sampling was applied. b) Review of an extensive collection of data generated within multiple previous studies.
doi:10.1371/journal.pone.0070919.g001
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Results
Molecular characterization of a random sample of 4,667
clinical TB isolates collected from the whole area of the Western
Cape, Eastern Cape and KwaZulu-Natal provinces of South
Africa revealed an increasing predomination of a single
genotype of strains from drug-sensitive to XDR-TB, in each
of the three provinces (Figure 2). In the Eastern Cape and
KwaZulu-Natal, the proportion of isolates belonging to the R86
and the F15/LAM4/KZN genotype, respectively, underwent a
27- and 44-fold increase from drug-susceptible to XDR-TB and
accounted for 95% and 72% of all XDR-TB cases (Figure 2,
Table S1). In the Western Cape, the percentage of R86 isolates
also increased significantly from drug-sensitive to XDR-TB
cases. However, a previous study indicated that R86 isolates
detected in the Western Cape, may to a large extent represent
TB patients from the economically depressed Eastern Cape
seeking treatment in the more affluent Western Cape [23].
Thus, if R86 isolates are disregarded, the R220 genotype most
strongly contributes to drug-resistant TB in the Western Cape,
in line with previous results [15]. Noteworthy, R220 isolates
expand significantly in proportion (24-fold) from drug-sensitive
to mono-/poly-resistant TB (Figure 2, Table S1).
Genotypes predominant in XDR-TB were infrequently detect-
ed among drug-sensitive TB cases (Figure 2). In all three provinces
investigated, R220, R86 and F15/LAM4/KZN strains accounted
for less than 5% of the drug-sensitive TB cases, making them
considerably less abundant than the typical Beijing, LAM3 and T1
genotypes, which each represented between 10% and 41% of all
drug-sensitive isolates (Table S1). Interestingly, while the strain
population structure among MDR-TB isolates was fundamentally
different between the three provinces [23], it appeared to be
similar for drug-sensitive isolates (Figure 2).
Drug resistance patterns of XDR-TB associated genotypes were
analysed by assessing the presence of commonly observed
resistance mutations in the inhA promoter and the genes katG,
Figure 2. Strain population structure of drug-sensitive (DS), mono-/poly-resistant (DR), sensu stricto multidrug-resistant (MDR s.s.;
excluding identified pre-XDR and XDR isolates), pre-extensively drug-resistant (pre-XDR) and extensively drug resistant (XDR)
isolates in three provinces of South Africa. The R220, R86 and F15/LAM4/KZN genotypes, respectively, represent a subgroup of the typical
Beijing, ‘‘atypical’’ Beijing and LAM4 family [14–16,22–24]. Based on similar IS6110 RFLP patterns and whole genome sequencing data it was
previously shown that ‘‘atypical’’ Beijing strains in the Western and Eastern Cape, unlike in other parts of the world, represent one single genotype
herein referred to as R86 [23,25,27]. The specific presence of R220 and F15/LAM4/KZN genotypes was only assessed in the Western Cape and
KwaZulu-Natal, respectively, where these genotypes were known to be frequent among XDR-TB cases [22].
doi:10.1371/journal.pone.0070919.g002
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rpoB, pncA, embB, rrs and gyrA (Table 1). A random sample of 193
MDR isolates of the R86 genotype from the Eastern Cape and 41
conveniently selected MDR isolates from the Western Cape
representing a variety of different Beijing genotypes (R86, R220
and other typical Beijing strains) were selected (Figures 1, 3 and 4).
Apart from H and R resistance mutations, various additional
resistance-conferring mutations were detected. Moreover, muta-
tion patterns were highly clustered (Figures 3 and 4). Most
strikingly, 69% of the R86 isolates from the Eastern Cape analyzed
(133/193 MDR isolates analyzed) harboured as many as seven
identical resistance mutations in the inhA promoter and the genes
katG, rpoB, pncA, embB and rrs suggesting that this cluster represents
a commonly transmitted pre-XDR strain resistant to at least H, R,
Z, E, S, Eto, Km, amikacin (Am) and capreomycin (Cm) (Table 1,
Figure 3) [23,27]. XDR-TB cases that have emerged from
infection with this strain showed a variety of different gyrA
mutations, suggesting that FQ resistance was acquired subse-
quently and perhaps due to the mismanagement of primary pre-
XDR-TB. Nevertheless, a sub-group of 44 isolates showed for
example an identical gyrA D94G mutation, potentially indicating
community spread of XDR strains (Figure 3).
A second cluster representing 17% of the R86 isolates from the
Eastern Cape (32/193 MDR isolates analyzed), was characterized
by identical mutations in katG, rpoB, pncA, embB and rrs conferring
resistance to H, R, Z, E and S (Table 1; Figure 3) [27].
Presumably, a sub-branch of this strain subsequently acquired
resistance to Eto through an inhA promoter mutation [38], to Km,
Am and Cm through an additional mutation in rrs [39,40] and
finally to FQs due to the acquisition of a gyrA A90V resistance
mutation (Figure 3) [6,41].
Analysis of the drug resistance mutation patterns of a
convenience sample of 41 MDR Beijing isolates from the Western
Cape, revealed that the two major R86 clusters detected in the
Eastern Cape were also present in this province, albeit at a
different relative frequency (Figures 3 and 4). For the remaining
R220 and other typical Beijing isolates analyzed, clustered
mutation patterns for at least pncA and embB were found in 8 out
of 16 cases (Figure 4), indicating a widespread combined presence
of Z and E resistance among these strains, in the Western Cape.
The clusters of strains defined above by genotype and drug
resistance mutation patterns (Figures 3 and 4) were geographically
widespread within the Eastern and Western Cape (Table 2),
indicating historical spread. In the Eastern Cape, the two
predominant clusters among MDR isolates of the R86 genotype
were detected in four and three different municipal districts,
respectively. In the Western Cape, despite the small sample size,
Figure 3. Drug resistance mutation pattern in a random selection of 193 MDR R86 isolates from the Eastern Cape. Different colours
indicate different drug resistance associated genes. The area of the circles is proportional to the number of isolates (indicated in the centre of each
circle) harbouring an identical drug resistance mutation for the respective resistance gene as well as all circles connected to the left. Principal
branches of the tree were defined by resistance mutations in pncA. Other first-line drug resistance mutations were connected by logical deduction to
maximize clustering and were followed by second-line resistance mutations. However, the order of acquisition of resistance mutations may remain
debatable in some cases.
doi:10.1371/journal.pone.0070919.g003
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isolates of four out of five clusters as defined by distinct pncA
mutations were identified in more than one district (Table 2).
Discussion
The present data shows a strong association between distinct
strain genotypes and the emergence of XDR-TB in three
neighbouring provinces of South Africa [23]. XDR-TB associ-
ated genotypes were infrequently found among drug-sensitive
TB cases, of which typical Beijing, LAM3 and T1 were the most
prevalent genotypes in all three provinces (Figure 2). This
observation is counterintuitive, if it was supposed that the
proportion of genotypes causing XDR-TB was a result of
random fluctuations. Under such conditions it would be
plausible to assume that genotypes predominant among drug-
sensitive TB cases would have been more likely to become
overrepresented among XDR-TB cases (Table 2, Figure 2).
Instead, the association of the R220, R86 and F15/LAM4/
KZN genotypes with XDR-TB suggests an increased ability of
these strains to acquire multiple drug-resistance mutations or to
transmit as drug-resistant strains. However, the relatively distant
phylogenetic relationship of these XDR-TB associated strain
genotypes [42,43] argues against the possibility of genetic
background accounting for this observation.
Drug resistance mutation patterns of isolates of XDR-TB
associated genotypes in the Eastern and Western Cape provinces
were highly clustered (Figure 3). Unfortunately, isolates of the
XDR-TB associated F15/LAM4/KZN genotype in KwaZulu-
Natal were not further characterized within this study and
therefore the relationship between genotype and clustering could
not be evaluated. However, in line with our observations for the
Western and Eastern Cape, a previous whole genome sequence
analysis of nine XDR F15/LAM4/KZN isolates from patients of
different settings in KwaZulu-Natal revealed nearly identical
genome sequences including matching drug resistance mutations
[26]. Together, this data suggests that in South Africa, XDR-TB
emerges mainly due to ongoing transmission of specific MDR s.s.
or pre-XDR genotypes that are sub-optimally treated by
programmatic treatment regimens, or partly, directly through
the transmission of XDR strains of these genotypes [11,25,27].
It is likely however, that our analyses convey a relative
overestimate of the proportion of transmission of primary pre-
XDR and XDR strains as the Km/Am/Cm resistance mutation
(rrs 1401 ARG) and the FQ resistance mutations (gyrA D94G and
Figure 4. Drug resistance mutation pattern in a convenience sample of 41 MDR Beijing isolates from the Western Cape. No data was
available for the streptomycin resistance determining region in rrs (Table 1). For more information see figure legend of Figure 3.
doi:10.1371/journal.pone.0070919.g004
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the gyrA A90V) detected among the largest clusters of isolates,
belong to the most frequently observed resistance mutations for
these drugs [6,44]. Indeed, for the Km/Am/Cm resistance
mutations observed in rrs, only a very low diversity was observed
(Figures 3 and 4) [39,40]. Thus, it is likely that these mutations
have been acquired independently multiple times among clustered
isolates and clustering may not (or to a lesser extent) represent the
clonal spread of pre-XDR and XDR strains.
Even if FQ and Km/Am/Cm resistance mutations in gyrA and
rrs are disregarded, 72% (139/193) and 8% (15/193) of the MDR
R86 isolates from the Eastern Cape belonged to one of two major
clusters of isolates harbouring identical resistance mutations to at
least H, R, Z, E, S and Eto (Figure 3). Similarly, altogether 63%
(26/41) of the MDR Beijing isolates from the Western Cape tested
belonged to one of altogether five clusters of isolates with identical
resistance mutations to at least H, R, Z, E, and Eto (Figure 4).
Given this data and the frequency distribution of different
genotypes among MDR-TB cases (Table 2), we can estimate that
at least 48% and 28% of all MDR-TB cases in the Eastern and
Western Cape, respectively, were caused by a strain resistant to at
least H, R, Z, E, S and Eto at the time of infection. Considering
published whole genome sequences of XDR F15/LAM4/KZN
isolates [26] and if FQ and Km/Am/Cm resistance mutations are
disregarded, this genotype also shows primary resistance to at least
H, R, E, Z, S and Eto and accounts for 26% of all MDR-TB cases
in KwaZulu-Natal (Table 2). Importantly, since only specific
XDR-TB associated genotypes were analyzed, the proportion of
MDR-TB cases with resistances to additional anti-TB drugs than
H and R may be even higher.
Given the standard MDR-TB drug regimens in South Africa
(currently consisting of Ofx, Km, Eto, Trd/Cs and Z) and if
excluding rrs and gyrA mutations, TB patients infected with these
strains are exposed to three effective drugs only (Ofx, Km and Cs/
Trd); this is less than the four effective drugs recommended by the
WHO [45]. If many of these transmitting strains in fact also
harboured a primary rrs 1401 ARG mutation, the treatment
regimen would consist of two effective drugs only. Under these
conditions, even the standardized XDR-TB treatment regimen in
South Africa, currently consisting of moxifloxacin, Cm, Eto, para-
aminosalicylic acid and Cs/Trd would be inappropriate to treat
infected patients [20]. Noteworthy, the previous MDR-TB
regimen endorsed until 2010, which used E instead of Cs/Trd,
Table 2. Geographical distribution of selected clusters of isolates.
Province Genotype Drug resistance mutation pattern Municipal District NIsolate %
EC R86 katG S315T/rrs 513 ARC/pncA C14R/rpoB S531L/embB M306I Amathole 19 59.4
Nelson Mandela Bay 12 37.5
OR Tambo 1 3.1
EC R86 katG S315T/rrs 513 ARC/pncA C14R/rpoB S531L/embB M306I/inhA
promoter -15 CRT/rrs 1401 ARG/gyrA A90V
Amathole 7 70.0
Nelson Mandela Bay 2 20.0
OR Tambo 1 10.0
EC R86 katG S315T/rrs 513 ARC/pncA 172 G insertion/inhA promoter -17
GRT/embB M306I/rpoB D516V/rrs 1401 ARG
Amathole 30 22.6
Cacadu 12 9.0
Chris Hani 1 0.8
Nelson Mandela Bay 90 67.7
EC R86 katG S315T/rrs 513 ARC/pncA 172 G insertion/inhA promoter -17
GRT/embB M306I/rpoB D516V/rrs 1401 ARG/gyrA D94G
Amathole 9 20.5
Cacadu 3 6.8
Chris Hani 1 2.3
Nelson Mandela Bay 31 70.5
WC R86 pncA C14R/inhA promoter -15 CRT/rpoB S531L/embB M306I/katG
S315T/rrs 1401 ARG
Cape Town 12 92.3
Eden 1 7.7
WC R86 pncA 172 G insertion/inhA promoter -17 GRT/rpoB D516V/embB
M306I/katG S315T/rrs 1401 ARG
Cape Town 3 75.0
Eden 1 25.0
WC R220 inhA promoter -15 CRT/rpoB S531L/pncA Y103Stop Cape Town 2 66.7
Overberg 1 33.3
WC R220 inhA promoter -15 CRT/pncA 153 large deletion/embB M306V Cape Town 2 66.7
Cape Winelands 1 33.3
WC Other typical
Beijing
katG S315T/rpoB S531L/pncA T100I/embB M306I Cape Town 3 100.0
EC: Eastern Cape Province.
WC: Western Cape Province.
Nisolate: Number of isolates of a cluster detected in the municipal district indicated.
%: Proportion of isolates of a cluster detected in the municipal district indicated.
doi:10.1371/journal.pone.0070919.t002
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resulted in an even higher chance of resistance development as it
consisted of only two or one effective drug, respectively. This clearly
demonstrates the inadequacy of current treatment regimens in
South Africa to prevent spread of XDR-TB associated strains and
calls for an immediate adaptation of MDR treatment algorithms.
Moreover, our findings highlight the urgent need for rapid first- and
second-line DST for all TB cases at treatment onset.
A likely scenario for the evolution of XDR-TB associated strains
in South Africa is depicted in Figure 5. It could be speculated that
the use of non-standardized drug regimens before 2002 facilitated
the emergence and transmission of strains with different resistance
patterns. Possibly, the implementation of standardized MDR-TB
treatment subsequently promoted the spread of strains harbouring
resistances against which the regimen was less effective. These
strains could have emerged originally as early as in the 1950’s
when TB treatment was not well controlled and mostly included
H, S and para-aminosalicylic acid only [46]. This is supported by
the very widespread presence of identical H and S resistance
mutations in isolates from the Eastern Cape, indicating that these
mutations were acquired at an initial stage (Figure 3). However,
importantly, improved TB control and standardized MDR-TB
treatment probably curbed the emergence of new resistant strains
and transmission of strains harbouring unfavourable resistance
patterns. Thus, the programmatic use of an only variably effective
MDR-TB treatment regimen could explain the predomination of
only a few strain families among XDR-TB cases. Although an
impact of strain genetic background on the propensity to develop
MDR/XDR-TB has been suggested [47], according to this model,
the acquisition of advantageous resistance patterns would have
occurred by chance and independent of strain genetic background,
explaining the association of different, distantly related genotypes
with XDR-TB in different provinces. Associations of a few specific
genotypes with MDR and XDR-TB were observed in several
countries throughout the world [48–51], suggesting similar
mechanisms for the emergence of XDR-TB.
This work highlights the value of molecular epidemiological
tools to perform drug resistance surveys and to decipher how
individual resistances may be linked and transmitted. Moreover,
this data will help designing more effective and urgently needed
MDR-TB treatment regimens for South Africa. Failure to do so
will rapidly enhance spread and amplification of resistance among
XDR-TB associated strains.
Supporting Information
Table S1 Strain population structure in the Western
Cape, Eastern Cape and KwaZulu-Natal Provinces of
South Africa.
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